A detailed history of Shell Asset Management CO transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 9,342 shares of SUPN stock, worth $332,575. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,342
Previous 9,876 5.41%
Holding current value
$332,575
Previous $264,000 10.23%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$25.77 - $35.16 $13,761 - $18,775
-534 Reduced 5.41%
9,342 $291,000
Q1 2024

Jul 31, 2024

SELL
$27.11 - $35.17 $16,862 - $21,875
-622 Reduced 5.92%
9,876 $264,000
Q1 2024

May 14, 2024

SELL
$27.11 - $35.17 $9,976 - $12,942
-368 Reduced 3.39%
10,498 $358,000
Q4 2023

Feb 14, 2024

SELL
$22.72 - $29.68 $74,544 - $97,380
-3,281 Reduced 23.19%
10,866 $314,000
Q3 2023

Nov 08, 2023

SELL
$27.57 - $32.91 $6,727 - $8,030
-244 Reduced 1.7%
14,147 $390,000
Q2 2023

Jul 28, 2023

SELL
$29.91 - $38.73 $2,422 - $3,137
-81 Reduced 0.56%
14,391 $433,000
Q1 2023

May 15, 2023

SELL
$34.93 - $42.03 $1,746 - $2,101
-50 Reduced 0.34%
14,472 $524,000
Q4 2022

Feb 07, 2023

SELL
$31.09 - $37.88 $96,503 - $117,579
-3,104 Reduced 17.61%
14,522 $518,000
Q3 2022

Nov 14, 2022

SELL
$28.79 - $35.41 $132,606 - $163,098
-4,606 Reduced 20.72%
17,626 $597,000
Q2 2022

Aug 09, 2022

BUY
$25.33 - $34.25 $1,139 - $1,541
45 Added 0.2%
22,232 $643,000
Q1 2022

May 04, 2022

SELL
$28.51 - $32.9 $93,541 - $107,944
-3,281 Reduced 12.88%
22,187 $717,000
Q4 2021

Feb 09, 2022

BUY
$26.37 - $34.22 $2,847 - $3,695
108 Added 0.43%
25,468 $743,000
Q3 2021

Nov 04, 2021

SELL
$23.54 - $31.39 $25,658 - $34,215
-1,090 Reduced 4.12%
25,360 $676,000
Q2 2021

Aug 12, 2021

BUY
$26.72 - $33.19 $38,209 - $47,461
1,430 Added 5.72%
26,450 $814,000
Q1 2021

May 10, 2021

BUY
$24.15 - $31.45 $115,267 - $150,110
4,773 Added 23.57%
25,020 $655,000
Q3 2020

Nov 13, 2020

BUY
$20.2 - $25.05 $103,989 - $128,957
5,148 Added 34.09%
20,247 $422,000
Q2 2020

Aug 10, 2020

BUY
$17.09 - $24.89 $258,041 - $375,814
15,099 New
15,099 $359,000
Q3 2019

Nov 12, 2019

SELL
$25.47 - $33.37 $775,204 - $1.02 Million
-30,436 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$29.96 - $38.87 $20,702 - $26,859
-691 Reduced 2.22%
30,436 $1.01 Million
Q4 2018

Feb 13, 2019

SELL
$30.84 - $49.51 $80,184 - $128,726
-2,600 Reduced 7.71%
31,127 $1.03 Million
Q3 2018

Nov 13, 2018

SELL
$42.7 - $56.55 $574,955 - $761,445
-13,465 Reduced 28.53%
33,727 $1.7 Million
Q2 2018

Aug 10, 2018

SELL
$44.1 - $59.85 $113,204 - $153,634
-2,567 Reduced 5.16%
47,192 $2.82 Million
Q3 2017

Oct 20, 2017

BUY
$36.75 - $49.65 $1.83 Million - $2.47 Million
49,759
49,759 $1.99 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.